Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
>
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Millipore Corporation and Novozymes Form Strategic Alliance to Supply Animal-Free Cell Culture Supplements for Bioprocessing

Published: Tuesday, December 18, 2007
Last Updated: Tuesday, December 18, 2007
Bookmark and Share
Alliance will accelerate launch of new animal-free supplements and provide customers with a source of high performance cell culture products.

Millipore Corporation and Novozymes have announced an agreement to develop, market, and sell new, animal-free cell culture supplements for biopharmaceutical manufacturing.

The new products, to be marketed under the brand name CellPrime™, will be manufactured by Novozymes and sold through Millipore’s sales organization. The alliance expands the existing relationship between Millipore and Novozymes and will initially focus on developing recombinant human albumin and recombinant human transferrin.

Cell culture supplements help mammalian cells produce the proteins that form the basis of biologic drugs. Today, customers seeking to utilize defined, animal-free supplements in their biopharmaceutical production processes have limited options. The CellPrime™ products are designed to reduce risk and ease regulatory concerns for biopharmaceutical manufacturers. Additionally, these products will help to improve the consistency and productivity of customers’ industrial cell culture processes.

“Our expanded relationship with Novozymes broadens our commitment to develop a portfolio of high quality, animal-free alternatives that optimize productivity, address drug safety, and ease regulatory approval,” said Andrew Bulpin, Ph.D., Vice President of Millipore’s Upstream Bioprocessing Business Unit.

“Our CellPrime™ products will give customers a reliable, long-term supply of regulatory compliant supplements and address their desire to eliminate the use of animal-derived products in their manufacturing processes,” Mr. Bulpin continued.

“We are excited about expanding our relationship with Millipore given the company’s leading position in serving the biopharmaceutical manufacturing market,” said Peter Rosholm, Vice President of Novozymes Biopharma.

“By leveraging the strengths of both companies, we will accelerate the introduction and adoption of innovative new products and enable our customers’ to re-think their production processes. This collaboration further strengthens our position as a strategic partner for biopharmaceutical companies and broadens Novozymes’ biopharmaceutical product portfolio.”

The process of manufacturing biologic drugs such as monoclonal antibodies begins with growing mammalian cells in a bioreactor. These cells are cultured in media and require the addition of supplements to enable efficient production of therapeutic proteins that form the basis of biologic drugs.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Cellular Reprogramming – What the Future Holds
Advancements in cellular reprogramming are coming at a furious pace. Along with these scientific breakthroughs come new opportunities for the development of therapeutics, disease modeling, drug screening, and new pathways to personalized medicine.
Friday, July 23, 2010
Millipore Opens new Bioprocess Manufacturing Facility in Massachusetts
New facility will produce company’s Mobius® single-use product line used for biopharmaceutical manufacturing technologies.
Wednesday, June 10, 2009
Millipore Extends Exclusive License Agreement with University of Dundee
The ongoing collaboration will bring novel cell signaling tools and services to life science researchers worldwide.
Friday, October 10, 2008
ReNcell® VM Neural Stem Cell Line Models Parkinson’s Disease
Milipore announces the publication of a new discovery derived from its ReNcell VM neural stem cell line.
Tuesday, July 22, 2008
Millipore Launches Progenitor Cell-Enriched Primary Human Epithelial Cell Cultures
According to Company, these primary cell cultures are designed to provide an enriched population of progenitor cells from skin, cornea, and bladder epithelia.
Friday, April 18, 2008
Millipore Announces Stem Cell Tested Initiative
Millipore’s Stericup with Express PLUS membrane is the first available under this initiative.
Wednesday, December 05, 2007
Millipore Corporation Announces new ReNcell® Data from Collaboration with ReNeuron
Millipore releases new data concerning its ReNcell neural stem cell lines at the ISSCR meeting in Cairns, Australia on June 20, 2007.
Thursday, June 21, 2007
Scientific News
Therapeutic Approach Gives Hope for Multiple Myeloma
A new therapeutic approach tested by a team from Maisonneuve-Rosemont Hospital (CIUSSS-EST, Montreal) and the University of Montreal gives promising results for the treatment of multiple myeloma, a cancer of the bone marrow currently considered incurable with conventional chemotherapy and for which the average life expectancy is about 6 or 7 years.
Cat Stem Cell Therapy Gives Humans Hope
By the time Bob the cat came to the UC Davis veterinary hospital, he had used up most of his nine lives.
Bile Acid Supports Production of Blood Stem Cells
A research group at Lund University has been able to show that bile acid is transferred from the mother to the foetus via the placenta to enable the foetus to produce blood stem cells.
New Biomarker to Assess Stem Cells Developed
A research team led by scientists from UCL have found a way to assess the viability of 'manufactured' stem cells known as induced pluripotent stem cells (iPSCs). The team's discovery offers a new way to fast-track screening methods used in stem cell research.
Tricked-Out Immune Cells Could Attack Cancer
New cell-engineering technique may lead to precision immunotherapies.
Edited Stem Cells Offer Hope of Precision Therapy for Blindness
Findings raise the possibility of treating blinding eye diseases using a patient's own corrected cells as replacement tissue.
Hacking the Programs of Cancer Stem Cells
All tumor cells are the offspring of a single, aberrant cell, but they are not all alike.
Newfound Strength in Regenerative Medicine
A promising new approach uses direct mechanical stimulation to repair severely damaged skeletal muscles.
Mapping out Cell Conversion
Researchers develop algorithm that takes the field of cell reprogramming forward.
Donor's Genotype Controls the Differentiation of IPS Cells
Pluripotent stem cells derived from different cell types are equally susceptible to reprogramming, indicates a recent study by the University of Helsinki and the National Institute for Health and Welfare, Finland. However, the genotype of the donor strongly influences the differentiation of the stem cell.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!